Ceftaroline Cerebrospinal Fluid Penetration in the Treatment of a Ventriculopleural Shunt Infection: A Case Report
- PMID: 32461749
- PMCID: PMC7243901
- DOI: 10.5863/1551-6776-25.4.336
Ceftaroline Cerebrospinal Fluid Penetration in the Treatment of a Ventriculopleural Shunt Infection: A Case Report
Abstract
Pharmacokinetic data regarding ceftaroline fosamil (CPT) penetration into cerebrospinal fluid (CSF) are limited to a rabbit model (15% inflamed) and adult case reports. We describe serum and CSF CPT concentrations in a 21-year-old, 34.8 kg female, medically complex patient presented with a 4-day history of fevers (Tmax 39.2°C), tachypnea, tachycardia, fatigue, and a 1-week history of pus and blood draining from the ventriculopleural (VPL) shunt. A head CT and an ultrasound of the neck revealed septated complex fluid collection surrounding the shunt. Therapy was initiated with vancomycin and ceftriaxone. Blood and CSF cultures from hospital day (HD) 1 were positive for methicillin-resistant Staphylococcus aureus with a CPT MIC of 0.5 mg/L and a vancomycin MIC range of 0.5 to 1 mg/L. On HD 3, CPT was added. On HD 7, simultaneous serum (69.4, 44, and 30.2 mg/L) and CSF (1.7, 2.3, and 2.3 mg/L) concentrations were obtained at 0.25, 1.5, and 4.75 hours from the end of an infusion. Based on these concentrations, CPT CSF penetration ratio ranged from 2.4% to 7.6%. After addition of CPT, the blood and CSF cultures remained negative on a regimen of vancomycin plus CPT. On HD 14, a new left-sided VPL shunt was placed. The patient continued on CPT for a period of 7 days after the new VPL shunt placement. This case demonstrated CPT CSF penetration in a range of 2.4% to 7.6%, approximately half of the rabbit model. This allowed for CSF concentrations at least 50% free time > 4 to 6× MIC of the dosing interval with a dosing regimen of 600 mg IV every 8 hours in a 34.8 kg chronic patient and resulted in a successful clinical outcome with no identified adverse outcomes.
Keywords: CSF penetration; MRSA; case report; ceftaroline CSF concentrations; ceftaroline fosamil; pediatric; pharmacodynamics; pharmacokinetic.
Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2020.
Conflict of interest statement
Disclosure Jeffrey J. Cies PharmD, MPH is a consultant for Atlantic Diagnostic Laboratories and has received grants and/or honoraria from Allergan, Merck, Thermo Fisher Scientific, and Melinta. The other authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. There was no grant or funding to support this work.
References
-
- Ngo QN, Ranger A, Singh RN et al. External ventricular drains in pediatric patients. Pediatr Crit Care Med. 2009;10(3):346–351. - PubMed
-
- Adams DJ, Rajnik M. Microbiology and treatment of cerebrospinal fluid shunt infections in children. Curr Infect Dis Rep. 2014;16(10):427–428. - PubMed
-
- Kestle J, Drake J, Milner R et al. Long-term follow-up data from the Shunt Design Trial. Pediatr Neurosurg. 2000;33(5):230–236. - PubMed
-
- Kestle JR, Drake JM, Cochrane DD et al. Lack of benefit of endoscopic ventriculoperitoneal shunt insertion: a multicenter randomized trial. J Neurosurg. 2003;98(2):284–290. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials